MB
CMPX icon

MPM BioImpact’s Compass Therapeutics CMPX Stock Holding History

MPM BioImpact’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,075,970
Closed -$17.8M – 42
2025
Q3 		$17.8M Sell
5,075,970
-546,535
-10% -$1.73M 2.91% 14
2025
Q2 		$14.6M Sell
5,622,505
-2,820,278
-33% -$5.82M 2.53% 15
2025
Q1 		$16M Sell
8,442,783
-125,113
-1% -$333K 2.76% 14
2024
Q4 		$12.4M Buy
8,567,896
+2,926,002
+52% +$4.86M 1.76% 27
2024
Q3 		$10.4M Buy
5,641,894
+636,808
+13% +$794K 1.56% 23
2024
Q2 		$5.01M Buy
5,005,086
+3,033,684
+154% +$4.43M 0.78% 39
2024
Q1 		$3.9M Buy
+1,971,402
New +$3.41M 0.63% 38

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact's CMPX Position: Q4 2025 in Review

MPM BioImpact sold out of Compass Therapeutics (CMPX) in Q4 2025, closing a stake of 5,075,970 shares — an estimated $17.8M sold.

MPM BioImpact first reported a position in CMPX in Q1 2024 and held it in 7 quarters. The position peaked at $17.8M in Q3 2025. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • MPM BioImpact reported no remaining Compass Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 5,075,970 Compass Therapeutics shares in Q4 2025, an estimated $17.8M.
  • MPM BioImpact first reported a position in Compass Therapeutics in Q1 2024 and held it in 7 quarters.
  • MPM BioImpact's Compass Therapeutics position peaked at $17.8M in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.